Blueprint Medicines Corp

Health Care
Biotechnology: Pharmaceutical Preparations
www.blueprintmedicines.com

Earnings Score
Moat Score
Safety Score

Market Cap $5.97B
PE -47
Debt $401.44M
Cash $100.86M
EV $6.27B
FCF -$250.52M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$128.05M
EBIT	-$127.43M
ROE	-41%
ROA	-11%
FCF	-$250.52M
Equity	$313.15M
Growth Stability	1
PE	-46.65
PEG	-4.88K
PB	19.08
P/FCF	-23.85
P/S	13.75
Price/Cash	0.02
Debt/Equity	1.28
Debt/FCF	-1.6
Net Margins	-5%
Gross Margins	97%
Op. Margins	-29%
Earnings CAGR	0%
Sales Growth YoY	127%
Sales Growth QoQ	-7%
Sales CAGR	50%
FCF CAGR	0%
Equity CAGR	11%
Earnings Stability	0
Earnings Growth YoY	-58%

Earnings Growth QoQ	13%
Earnings CAGR 5Y	0%
Sales CAGR 5Y	12%
FCF CAGR 5Y	0%
Equity CAGR 5Y	-28%
Earnings CAGR 3Y	24%
Sales CAGR 3Y	24%
Equity CAGR 3Y	-42%
Market Cap	$5.97B
Revenue	$434.42M
Assets	$1.20B
Total Debt	$401.44M
Cash	$100.86M
Shares Outstanding	62.61M
EV	6.27B
Earnings Score	6%
Moat Score	7%
Safety Score	62%
Final Score	25%
Working Capital	597.19M
Current Ratio	3.32
Gross Profit	$421.44M
Shares Growth 3y	2%
Equity Growth QoQ	-2%
Equity Growth YoY	55%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates BLU-285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. Its other drug candidate is BLU 554 FOR Advanced Hepatocellular Carcinoma, and BLU-667 for Ret Mutations, Fusions, and Predicted Resistant Mutants.

SEC Filings

Direct access to Blueprint Medicines Corp (BPMC) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Blueprint Medicines Corp compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Blueprint Medicines Corp compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 0%

Stability 0%

loading chart...

Blueprint Medicines Corp Discounted Cash Flow

Fully customizable DCF calculator online for Blueprint Medicines Corp.

Years

Calculation mode

= -$2.5B

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	-$251M	-$251M	-$251M	-$251M	-$251M	-$251M	-$251M	-$251M	-$251M	-$251M	-$251M	-$2.5B
DCF		-$228M	-$207M	-$188M	-$171M	-$156M	-$141M	-$129M	-$117M	-$106M	-$97M	-$966M
Value	-$2.5B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	-	-491%	-261%	-691%	-532%	-523%	40%	-358%	-273%	-203%	-5%
ROA	-	-	-	-	-	-49%	18%	-51%	-41%	-48%	-11%
ROE	-	-39%	-34%	-24%	-56%	-75%	21%	-66%	-108%	-388%	-41%

Bad Net Margins (-4.73%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	-	-	-0.01	-	-	-	-	-0.84	-0.98	-1.6
Debt over Equity	-	-	-	0	-	-	-	-	0.84	3.38	1.28
Growth Stability	-	-	-	-	-	-	-	-	-	-	1

Good Debt/FCF ratio (-1.6)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Neutral Debt/Equity ratio (1.28)

The company has a balance between equity and debt that is not too good nor too bad.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	-	144%	-23%	108%	49%	1K%	-77%	13%	22%	12%
Earnings YoY growth	-	21%	30%	104%	60%	47%	-190%	-305%	-13%	-9%	0%
Equity YoY growth	-	-281%	48%	193%	-33%	11%	217%	-34%	-47%	-75%	-28%
FCF YoY growth	-	1%	-27%	404%	39%	56%	-231%	-179%	69%	-11%	0%